Renal function testing in people taking dabigatran
In this Audit
Dabigatran is an oral anticoagulant used primarily to prevent stroke in people with non-valvular atrial fibrillation (AF). It is an alternative treatment option to warfarin and appears to be at least as effective as warfarin for preventing stroke in patients with AF. Dabigatran has a similar rate of bleeding events to warfarin.1
Dabigatran is indicated for people with non-valvular atrial fibrillation for:
- Prevention of stroke
- Prevention of systemic embolism
- Reduction of overall vascular mortality
For these indications, pharmacological treatment should be continued for life unless the patient’s risk/benefit ratio changes.
Dabigatran is also registered for short-term use for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery. It provides an oral alternative to low molecular weight heparin, such as enoxaparin.
For further information on prescribing and monitoring dabigatran, see: : “The use of dabigatran in general practice: a cautious approach is recommended”, BPJ 38 (Sept, 2011).
Dabigatran is excreted by the kidneys
Up to 80% of circulating dabigatran is excreted, unchanged, by the kidneys. Therefore, any reduction in renal function can affect the plasma concentration of the medicine.
As renal function declines with age and most people taking dabigatran will be taking it for life, regular monitoring of renal health and function is essential to avoid serious adverse events, particularly bleeding. Creatinine clearance should be checked in all patients before treatment with dabigatran and patients with severe renal impairment (creatinine clearance < 30 mL/min) should not be prescribed dabigatran. Patients with impaired renal function (creatinine clearance 30 – 50 mL/min) should only be prescribed dabigatran with caution, and close monitoring will be required.
Any patient taking dabigatran, who has renal impairment or is at risk of developing renal impairment, should have their eGFR checked or creatinine clearance calculated at least annually during long-term treatment. The key criteria for renal assessment in people taking dabigatran are:
- Renal function must be assessed in all patients prior to the initiation of dabigatran
- For patients taking dabigatran, renal function should be rechecked in any clinical situation where a decline is suspected, e.g. dehydration, hypovolaemia and with some medicines, such as diuretics
- Renal function should be assessed at least annually in patients taking dabigatran aged over 75 years or with moderate renal impairment (creatinine clearance 30–50 mL/min)
Patients taking dabigatran with the following risk factors should have had at least one renal function assessment within the previous 12 months:
- Age over 75 years
- Moderate renal impairment (30 – 50 mL/min)
1. Barrios V, Scobar C. New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Exp Op Pharmaco 2012;35(18):2649-61.
Any patient with AF enrolled in primary care taking dabigatran for stroke prevention who is either over age 75 years or has moderate renal impairment.
Criteria for a positive result
The patient is currently taking dabigatran and has had a creatinine clearance test in the previous 12 months.
As the risk of bleeding is significant and the consequences of a bleed can be severe, at least 90% of patients should meet the requirements of a positive audit outcome.
Any person with AF who was prescribed dabigatran in primary care for stroke prevention, and is aged over 75 years OR has moderate renal impairment, is eligible for this audit.
You will need to have a system in place that allows you to identify eligible patients. Many practices will be able to identify patients by running a ‘query’ through their practice management software for patients who are currently taking dabigatran and then checking for read codes identifying renal impairment or checking patient notes for age or impairment. Depending on recording practices, the tests that were requested at the time of prescription or regularly since then can be then be found either within the query or from the patient notes.
The number of eligible patients will vary according to your practice demographic. If you identify a large number of patients, take a random sample of 30 patients whose notes you will audit (or the first 30 results returned).
Use the data sheet to record your data. Calculate your percentages by taking the number of people who are a “positive result” as per the audit criteria, divided by the total number of people audited (i.e. the 30 patients whose test choice was reviewed), multiplied by 100.
For example – 25 people were audited, 23 of whom had had their renal function tested in the previous 12 months. Therefore percentage is calculated as: 23/25 × 100 = 92%.
Identifying opportunities for CQI
The first step in taking action is to identify the criteria where gaps exist between expected and actual performance
and decide on priorities for change.
Once priority areas for change have been decided on, an action plan should be developed to implement any changes.
The plan should assign responsibility for various tasks to specific members of the practice team and should include a
It is important to include the whole practice team in the decision-making and planning process.
It may be useful to consider the following points when developing a plan for action (RNZCGP 2002).
Problem solving process
- What is the problem or underlying problem(s).
- Change it to an aim.
- What are the solutions or options?
- What are the barriers?
- How can you overcome them?
- Identifying barriers can provide a basis for change.
- What is achievable – find out what the external pressures on the practice are and discuss ways of dealing with them
in the practice setting.
- Identify the barriers.
- Develop a priority list.
- Choose one or two achievable goals.
- No single strategy or intervention is more effective than another, and sometimes a variety of methods are needed to
bring about lasting change.
- Interventions should be directed at existing barriers or problems, knowledge, skills and attitudes, as well as performance
- How can you overcome them?
Monitoring change and progress
It is important to review the action plan against the timeline at regular intervals with the practice team. It may be
helpful to discuss the following questions:
- Is the process working?
- Are the goals for improvement being achieved?
- Are the goals still appropriate?
- Do you need to develop new tools to achieve the goals you have set?
Following the completion of the first cycle, it is recommended that practices complete the first part of the CQI activity
summary sheet (Appendix 1).
Undertaking a second cycle
In addition to regular reviews of progress with the practice team, a second audit cycle should be completed in order
to quantify progress on closing the gaps in performance.
It is recommended that the second cycle be completed within 12 months of completing the first cycle. The second cycle
should begin at the data collection stage. Following the completion of the second cycle it is recommended practices complete
the remainder of the CQI activity summary sheet.
Claiming MOPS credits
This audit has been endorsed by the RNZCGP as an Audit of Medical Practice activity (previously known as Continuous
Quality Improvement - CQI) for allocation of MOPS credits; 10 credits for
a first cycle and 10 credits for a second cycle. General practitioners taking part in this audit can
claim credits in accordance with the current MOPS programme.
To claim points go to the RNZCGP website: www.rnzcgp.org.nz
Record your completion of the audit on the MOPS Online credit summary, under the
Audit of Medical Practice section.
From the drop down menu, select the audit from the list or select “Approved practice/PHO audit” and record the audit name in “Notes”, the audit date and 10 credits.
General practitioners are encouraged to discuss the outcomes of the audit with their peer group or practice.
As the RNZCGP frequently audit claims you should retain the following documentation, in order to provide adequate evidence of participation in this audit:
- A summary of the data collected
- An Audit of Medical Practice (CQI) Activity summary sheet (included as Appendix 1).